Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting Abstract #1244

Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Aim(s): We performed a retrospective analysis to evaluate medians(m) of progression free survival(PFS)and safety in metastatic pNET pts treated with everolimus in the real life setting
Materials and methods: Consecutive pts with progressive metastatic pNET treated at Gustave Roussy(Villejuif, France)from January 2006 to August 2014 with everolimus were analyzed. Primary end-points were mPFS. Secondary objective were mOS, best response according to Response Evaluation Criteria in Solid Tumor(RECIST v.1.1) and safety according to the National Cancer Institute Common Toxicity Criteria (CTCAE v.4.0)
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Michela Del Prete

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result